3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Basal Cell Nevus Syndrome
2
Skin Neoplasms
1
Pancreatic Diseases
1
Multiple Myeloma
1
Medulloblastoma
1
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
8
Paclitaxel
8
Carboplatin
6
Megestrol Acetate
4
niraparib
3
Cisplatin
3
tislelizumab
2
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
2
rucaparib
2
olaparib
2
iso-sulfan blue
2
copanlisib
2
Taxes
2
Surveys and Questionnaires
2
Nivolumab
2
Lymph Node Excision
2
Indocyanine Green
2
Fulvestrant
2
Filgrastim
2
Doxorubicin
2
Docetaxel
2
tremelimumab
1
spartalizumab
1
sonidegib
1
ribociclib
1
rebastinib
1
pemigatinib
1
nicotinamide-beta-riboside
1
lenvatinib
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Endometrial Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts